Drugs / DOR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04233216 | Mar 2020 → Nov 2022 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04233216 ↗ |
| Route | Oral | “taken by mouth” NCT04233216 ↗ |